Sunitinibmalat hæmmer gentagne receptortyrosinkinaser (RTK), som indgår i tumorvækst, patologisk angiogenese og metastaserende progression af cancer.
Sunitinib malate inhibits multiple receptor tyrosine kinases (RTKs) that are implicated in tumour growth, pathologic angiogenesis, and metastatic progression of cancer.